**Abstract**

Hyperprolactinemia (HPRL) is a common side effects of antipsychotic drugs. It is primarily attributed to blockade of DRD2 within the pituitary gland. Although dopamine is considered the primary prolactin (PRL) release inhibiting factor, the activity of PRL producing lactotrophs is also regulated by the secregogues: thyrotrophin releasing hormone, vasoactive intestinal polypeptide and serotonin (5-HT).

The aim of our study was to investigate the association between 5-HT receptor variants and hyperprolactinemia in antipsychotic drug treated patients with schizophrenia.

The study group included 446 Caucasian persons (M 221/F 225) with a clinical diagnosis of schizophrenia, who were treated with classical and/or atypical antipsychotic drugs. Prolactin level was determined with ELISA method. The upper limits for normal PRL concentration were set at ≤ 20 ng/ml for men and ≤ 25 ng/ml for women. We selected a subset of 29 SNPs, that would accurately represent the majority of SNPs for the following serotonin receptors genes: HTR1A, HTR1B, HTR2A, HTR2C, HTR3A, HTR3B, HTR6. DNA extraction and genotyping were conducted according to standard protocols and blind to the clinical status of the subjects. The software "R" and SPSS were used for statistical analysis.

None of the studied autosomal markers was found to be associated with HPRL. However, a statistically significant association was established between various HTR2C polymorphisms and HPRL. As a result of the analysis of association between HPRL and haplotypes of X-chromosome SNPs, the most statistically significant association was found for a combination of the rs569959\*G and rs17326429\*A alleles.

It is unlike, that our results are invalidated by the binding potential of the antipsychotic drug used by the patients. We found no clear evidence that the studied HTR2C variants correspond to lack of constitutive activity of this receptor.
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